By: Elai Katz, Lisa P. Rumin & Betty Zhang (McDermott Will & Emery Antitrust Alert)
Pharmaceutical patent holders take note: Over the past year, antitrust enforcers have intensified their scrutiny of Orange Book listings, viewing them as potentially anticompetitive. The Federal Trade Commission has stated that improperly listing patents in the Orange Book can constitute an unfair method of competition, among other legal violations.
In this article, Elai Katz, Lisa Rumin, and Betty Zhang examine this increased focus on Orange Book listings and outline the risks brand-name drug manufacturers should be mindful of regarding their listing practices. Moving forward, these manufacturers should adopt a proactive approach by thoroughly documenting their evaluation process and the rationale behind listing patents in the Orange Book to ensure compliance with statutory requirements…
Featured News
Electrolux Fined €44.5 Million in French Antitrust Case
Dec 19, 2024 by
CPI
Indian Antitrust Body Raids Alcohol Giants Amid Price Collusion Probe
Dec 19, 2024 by
CPI
Attorneys Seek $525 Million in Fees in NCAA Settlement Case
Dec 19, 2024 by
CPI
Italy’s Competition Watchdog Ends Investigation into Booking.com
Dec 19, 2024 by
CPI
Minnesota Judge Approves $2.4 Million Hormel Settlement in Antitrust Case
Dec 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand